Elevance Health Aktie
| 400,47USD | -4,89USD | -1,21% |
WKN DE: A12FMV / ISIN: US0367521038
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,78 |
| The Vanguard Group, Inc. | 9,15 |
| Vanguard Group, Inc. (Subfiler) | 8,76 |
| State Street Corp. | 4,61 |
| T. Rowe Price Associates, Inc. (IM) | 4,39 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 4,22 |
| Vanguard Total Stock Market ETF | 3,14 |
| BlackRock Fund Advisors | 2,73 |
| Vanguard 500 Index Fund | 2,71 |
| BlackRock Institutional Trust Co. NA | 2,27 |
| Geode Capital Management LLC | 2,09 |
| Sanders Capital LLC | 1,99 |
| Wellington Management Co. LLP (Wellington Breakout) | 1,84 |
| Capital Research & Management Co. (International Investors) | 1,66 |
| Norges Bank (13F) | 1,31 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 83 400 | 98 200 | 102 300 | 104 900 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,46 | 1,41 | 1,53 | 1,63 | 0,00 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 45 751 | 51 122 | 55 617 | 60 029 | 58 726 |
| Summe Anlagevermögen | 42 525 | 46 338 | 47 155 | 48 899 | 57 947 |
| Summe Aktiva | 88 276 | 97 460 | 102 772 | 108 928 | 116 673 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 55 077 | 61 332 | 66 378 | 69 523 | 75 247 |
| Summe Eigenkapital | 33 199 | 36 128 | 36 394 | 39 405 | 41 426 |
| Summe Passiva | 88 276 | 97 460 | 102 772 | 108 928 | 116 673 |
Adresse
| 220 Virginia Avenue, 46204 Indianapolis | |
| Telefon | +1 (800) 331-1476 |
| Internet | http://www.elevancehealth.com |
Management
|
Antonio Fabio Neri
Independent Director |
|
Bahija Jallal
Independent Director |
|
Blair W. Todt
Executive VP, Chief Legal & Administrative Officer |
|
Bryony Winn
President-Health Solutions |
|
Chris Rigg
Senior VP & CFO-Commercial & Specialty Business |
|
Deanna Dawnette Strable-Soethout
Independent Director |
|
Dustin Wilcox
Chief Information Security Officer |
|
Elizabeth E. Tallett
Independent Chairman |
|
Felicia Farr Norwood
EVP & President-Government Health Benfits |
|
Gail Koziara Boudreaux
President, Chief Executive Officer & Director |
|
Hakon Mattson
Chief Sustainability Officer |
|
Jill A. Becher
Vice President-Planning & Execution |
|
Kathleen S. Kiefer
Secretary & Chief Governance Officer |
|
Kyle Weber
Chief Strategy Officer |
|
Lewis Hay
Independent Director |
|
Marcus D. Wilson
Chief Analytics Officer |
|
Mark B. Kaye
Chief Financial Officer & Executive Vice President |
|
Morgan Kendrick
EVP & President-Commercial & Specialty Business |
|
Nathan Rich
Vice President-Investor Relations |
|
Peter David Haytaian
Executive VP, President-Carelon & CarelonRX |
|
R. Kerry Clark
Independent Director |
|
Rachel Stuve
Sr. Director Data Science & AI |
|
Ramiro G. Peru
Independent Director |
|
Ratnakar Lavu
Chief Digital Information Officer & Executive VP |
|
Robert L. Dixon
Independent Director |
|
Ronald William Penczek
Chief Accounting Officer & Controller |
|
Ryan M. Schneider
Independent Director |
|
Scott Towers
President-Dental Business |
|
Shantanu Agrawal
Chief Health Officer |
|
Susan D. DeVore
Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.